Related references
Note: Only part of the references are listed.Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
Yuichi Tambo et al.
CLINICAL LUNG CANCER (2020)
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
Claudio Martin et al.
CLINICAL LUNG CANCER (2020)
Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
R. Califano et al.
EUROPEAN JOURNAL OF CANCER (2020)
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
Karim Amrane et al.
CANCER MEDICINE (2020)
Pharmacotherapy within a learning healthcare system: rationale for the Dutch Santeon Farmadatabase
Ewoudt M. W. van de Garde et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2019)
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
Lucio Crino et al.
ONCOLOGIST (2019)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J. Antonia et al.
LANCET ONCOLOGY (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer
Francesco Grossi et al.
EUROPEAN JOURNAL OF CANCER (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti et al.
IMMUNOTHERAPY (2019)
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry
H.J.M. Smit et al.
LUNG CANCER (2019)
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
Sirisha L. Mushti et al.
CLINICAL CANCER RESEARCH (2018)
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Aaron Lisberg et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
K. Al-Baimani et al.
CURRENT ONCOLOGY (2018)
Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness
Jacqueline Corrigan-Curay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
Christine M. Cramer-van der Welle et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality
Rebecca A. Miksad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Benjamin Herzberg et al.
ONCOLOGIST (2017)
Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov
Aidan Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Management of lung cancer in older adults
A Hurria et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2003)
Share Paper
